Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel orally active oxytocin receptor antagonist profiled at GlaxoSmithKline

Jan. 23, 2007

AnGes inlicenses Naglazyme for Japan

Jan. 23, 2007

Bionovo opens pharmacokinetics study of MF-101

Jan. 23, 2007

Pivotal study evaluates Aastrom's TRCs for osteonecrosis of the femoral head

Jan. 22, 2007

GPAT suggested as a new target for obesity treatment

Jan. 19, 2007

Japanese approval sought for Actos with biguanides

Jan. 19, 2007

Clinical trial will evaluate the effects of betahistine on body weight

Jan. 19, 2007

Recent patents disclose novel metabolic drugs

Jan. 19, 2007

European Commission approves Tandemact

Jan. 19, 2007

Treatment completed in acute portion of pivotal HAE study of C1-INH

Jan. 19, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...